Slate Path Capital LP Cue Biopharma, Inc. Transaction History
Slate Path Capital LP
- $4.98 Billion
- Q1 2024
A detailed history of Slate Path Capital LP transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Slate Path Capital LP holds 2,402,455 shares of CUE stock, worth $2.98 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
2,402,455
Previous 2,402,455
-0.0%
Holding current value
$2.98 Million
Previous $6.34 Million
28.41%
% of portfolio
0.09%
Previous 0.14%
Shares
4 transactions
Others Institutions Holding CUE
# of Institutions
78Shares Held
16.3MCall Options Held
12.9KPut Options Held
39.1K-
Bleichroeder LP New York, NY2.76MShares$3.42 Million1.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$2.83 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.24MShares$2.78 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA839KShares$1.04 Million0.0% of portfolio
-
State Street Corp Boston, MA760KShares$942,1450.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $43.9M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...